Combined pulmonary fibrosis and emphysema: an increasingly recognized condition*,**

Combinación de fibrose pulmonar e enfisema: uma doença cada vez mais reconhecida

Olivia Meira Dias, Bruno Guedes Baldi, André Nathan Costa, Carlos Roberto Ribeiro Carvalho

Abstract

Combined pulmonary fibrosis and emphysema (CPFE) has been increasingly recognized in the literature. Patients with CPFE are usually heavy smokers or former smokers with concomitant lower lobe fibrosis and upper lobe emphysema on chest HRCT scans. They commonly present with severe breathlessness and low DLCO, despite spirometry showing relatively preserved lung volumes. Moderate to severe pulmonary arterial hypertension is common in such patients, who are also at an increased risk of developing lung cancer. Unfortunately, there is currently no effective treatment for CPFE. In this review, we discuss the current knowledge of the pathogenesis, clinical characteristics, and prognostic factors of CPFE. Given that most of the published data on CPFE are based on retrospective analysis, more studies are needed in order to address the role of emphysema and its subtypes; the progression of fibrosis/emphysema and its correlation with inflammation; treatment options; and prognosis.

Keywords: Pulmonary fibrosis; Emphysema; Hypertension, pulmonary; Lung diseases, interstitial.

Introduction

Idiopathic pulmonary fibrosis (IPF) and pulmonary emphysema are distinct clinicopathological entities that pulmonologists have long been familiar with. Since the advent of HRCT, the combination of these two conditions has been increasingly described and has been proven to be a prevalent and distinct entity rather than a rare coincidence.

The association of IPF and emphysema was initially described in 1990 by Wiggins et al.,[1] who described eight heavy smokers with fibrosis and upper lobe emphysema on HRCT scans, together with severe breathlessness, strikingly low DLCO, and preserved lung volumes. In 2005, Grubstein et al.[2] reported an association of fibrosis with emphysema in eight patients, their clinical and functional findings being similar to those of the aforementioned study. The authors also found moderate to severe pulmonary arterial hypertension (PAH) and postulated that smoking is a factor

*Study carried out in the Department of Pulmonology, Instituto do Coração – InCor, Heart Institute – University of São Paulo School of Medicine Hospital das Clinicas, São Paulo, Brazil.
Correspondence to: Olivia Meira Dias. Rua Doutor Enéas de Carvalho Aguiar, 44, 5º andar, CEP 05403-900, São Paulo, SP, Brasil.
Tel. 55 11 3069-5000. E-mail: meiradias@yahoo.com.br
Financial support: None.
Submitted: 6 May 2014. Accepted, after review: 19 May 2014.
**A versão completa em português deste artigo está disponível em www.jornaldepneumologia.com.br
Combined pulmonary fibrosis and emphysema: an increasingly recognized condition

The term combined pulmonary fibrosis and emphysema (CPFE) was first used in 2005 by Cottin et al., who characterized a homogeneous group of 61 patients with CT findings of emphysema in the upper zones and interstitial lung disease (ILD) with pulmonary fibrosis in the lower lobes. When CPFE was first described, patients with other ILDs were excluded from the study. Later on, CPFE was described in patients with other ILDs, such as connective tissue disease (CTD)-associated ILD, as well as in patients with microscopic polyangiitis.

Studies have shown that patients with CPFE associated with CTDs (especially rheumatoid arthritis and systemic sclerosis) are significantly younger than their idiopathic CPFE counterparts, are predominantly female, and have less DLCO impairment. One group of authors found elevated serum antinuclear antibodies with or without positive perinuclear antineutrophil cytoplasmic antibodies in CPFE patients when compared with IPF patients without emphysema, those with positive autoimmune markers exhibiting greater infiltration of CD20+ B cells forming lymphoid follicles in fibrotic lung tissue and improved survival when compared with those with negative autoimmune markers.

Given that tobacco exposure seems to modulate an underlying inflammatory response in patients with ILD, CPFE should be categorized as a pattern associated with other pulmonary diseases rather than as a primary idiopathic syndrome, a classification similar to the usual interstitial pneumonia (UIP) pattern in other fibrotic ILDs. In other words, the recognition of a CPFE pattern should also prompt the investigation of secondary autoimmune diseases and CTDs.

Patients with CPFE are predominantly male, with a history of heavy tobacco exposure, and usually present with severe breathlessness and cough. Physical examination reveals “Velcro” crackles at the lung bases and digital clubbing. Pulmonary hypertension is a hallmark of the syndrome and determines poor prognosis. Between January of 2006 and December of 2013, 17 patients were diagnosed with CPFE at our interstitial lung disease outpatient clinic, and the data are summarized in Table 1. In accordance with the literature, our patients were predominantly male (88%), the mean age at diagnosis being 68 years. All of the patients presented with tobacco exposure and dyspnea at diagnosis. Almost half of the patients had pulmonary hypertension diagnosed by echocardiography. Few (6%) had a diagnosis of lung cancer, and 12% died during the follow-up period.

Pathogenesis

The pathogenesis of CPFE has yet to be elucidated. Tobacco exposure per se can be an important fibrogenic stimulus, smoking having been shown to play a key role in the pathogenesis of several ILDs, including respiratory bronchiolitis-associated ILD (RB-ILD), desquamative interstitial pneumonia, pulmonary Langerhans cell histiocytosis, and, possibly, IPF.

Washko et al. conducted a lung cancer screening study involving a large cohort of COPD patients and found interstitial lung abnormalities on HRCT scans in up to 8% of smokers. Likewise, Katzenstein et al. reported frequent and severe interstitial fibrosis in over half of lobectomy specimens excised for lung cancer from smokers with no clinical evidence of ILD, even in those patients in whom emphysema was the only CT finding.

Those histological findings characterized a distinct, non-classifiable ILD, which Katzenstein et al. designated “smoking related-interstitial fibrosis”, characterized by thickening of alveolar septa by fibrosis composed mostly of hyalinized eosinophilic collagen bundles and surrounding enlarged airspaces of emphysema, as well as by signs of respiratory bronchiolitis. Although follow-up was short, the clinical progression

| Table 1 - Characteristics of 17 patients with combined pulmonary fibrosis and emphysema treated at the Interstitial Lung Disease Outpatient Clinic of the University of São Paulo School of Medicine Hospital das Clínicas between 2006 and 2013, together with the clinical manifestations of the disease. |
|------------------|------------------|
| Characteristic   | Result           |
| Male/Female      | 15 (88)/2 (12)   |
| Age at diagnosis, years | 68 ± 7          |
| Tobacco exposure | 17 (100)         |
| Dyspnea at diagnosis | 17 (100)       |
| Pulmonary hypertension at diagnosis | 8 (47)         |
| Hypoxemia at diagnosis | 11 (65)        |
| Lung cancer during follow-up | 1 (6)           |
| Deaths during follow-up | 2 (12)        |

Values expressed as n (%), except where otherwise indicated.
Values expressed as mean ± SD.
It is reasonable to assume that the lung parenchyma shows different patterns of injury and repair in response to tobacco exposure. The different phenotypes of lesions secondary to tobacco exposure depend on the balance of apoptosis, proteolysis, and fibrosis. Patients in whom genes related to connective tissue synthesis, structural constituents of the cytoskeleton, and cell adhesion are overexpressed typically display a fibrogenic phenotype, such as that found in patients with UIP; however, a different inflammatory response to smoking-associated cellular damage (destruction and repair of cells, vessels, and pneumocytes) leads to destruction of lung parenchyma, culminating in pulmonary emphysema. A combination of these two patterns of response can be found in patients with CPFE and has recently been demonstrated by gene expression analysis of fibrotic and emphysematous lesions in such patients.

The role of environmental exposure as a potential trigger of lung injury is also plausible, given that some CPFE patients have had significant exposure to agrochemical compounds that cause airway damage and ILD in genetically susceptible smokers. Some authors have described CPFE as an occupational disease, e.g., in patients exposed to talc and in welders.

The signaling pathways to these responses are unknown. Laboratory animal studies have demonstrated that oxidative stress inducing inflammatory cell activation, elevated matrix metalloproteinase levels causing proteolytic activity, and overexpression of other mediators, such as PDGF, TNF-α, and TGF-β, are potential pathways explaining the lesions that lead to emphysema and fibrosis. A study analyzing inflammatory mediators in BAL fluid from patients with IPF showed significantly higher concentrations of chemokine (C-X-C motif) ligand 5 and chemokine (C-X-C motif) ligand 8 in those with concomitant HRCT findings of emphysema. These chemokines are associated with neutrophil accumulation in airspaces and suggest a different pathway of inflammation leading to the development of emphysematous changes superimposed on pulmonary fibrosis.

Genetic mutations have been described in CPFE patients with and without a significant smoking history. This indicates that risk factors other than tobacco smoking are associated with the development of CPFE or that tobacco smoking can be a triggering factor in susceptible patients. Plausible genetic pathways have been confirmed in case reports in which mutations in the surfactant protein C gene were identified in a 32-year-old female who had never smoked and an ABCA3 mutation was identified in a 41-year-old male nonsmoker, with CT findings identical to those in CPFE patients. These mutations are known to cause dysfunction of surfactant homeostasis and, consequently, injury or death of alveolar epithelial type II cells and myofibroblast proliferation.

Finally, reports have described CPFE features in a family with inherited telomerase mutations. These findings reinforce the idea of a combination of genetic predisposition and a triggering exposure (smoking) in susceptible individuals leading to continuous damage to alveolar epithelial cells that cannot be properly repaired, initiating a vicious cycle of attempts at alveolar regeneration and uncontrolled activation of fibrosis proliferation and parenchymal destruction.

**Imaging studies in CPFE**

Imaging studies are essential for the diagnosis of CPFE. Although routine chest X-rays are not as sensitive as HRCT scans, they can reveal an interstitial pattern predominantly in the subpleural and basal lung regions, with hyperlucency in the lung apices corresponding to emphysematous areas.

The mainstay of the diagnosis of CPFE, HRCT scans typically show centrilobular or paraseptal emphysema in the upper lobes, as well as reticular opacities, traction bronchiectasis, septal thickening, ground-glass opacities, and honeycombing in the lower lobes (Figures 1 and 2). Although UIP is the most common CT pattern, some patients have ground-glass opacities that are more extensive than expected for a UIP pattern and are therefore suggestive of nonspecific interstitial pneumonia, RB-ILD, and even desquamative interstitial pneumonia.

Brillet et al. described patterns of distribution of fibrosis and emphysema in patients with CPFE other than those initially described: a progressive transition from apical emphysema to a zone of transition between bullae and honeycombing; paraseptal emphysema with areas of fibrosis;
and separate processes with independent areas of fibrosis and emphysema.\textsuperscript{[27]}

**Lung function in CPFE**

Regarding the lung function of patients with CPFE, spirometry can be normal or show mild abnormalities, FVC, FEV\textsubscript{1}, and TLC values usually being within normal ranges or slightly altered.\textsuperscript{[1,28]} The FEV\textsubscript{1}/FVC ratio can be within or slightly below the normal range. Severely impaired DLCO and hypoxemia during exercise are common.\textsuperscript{[3,28]}

Silva et al. reported similar findings in a retrospective cohort of 11 Brazilian patients, spirometry having revealed normal lung volumes in 7.\textsuperscript{[29]} At our facility, 17 CPFE patients were evaluated, and spirometry showed normal lung function and lung volumes in 12\%, an obstructive pattern in 18\%, and a restrictive pattern in 47\%. All patients had reduced DLCO (Table 2).

In a five-year follow-up study of 16 CPFE patients, the annual decline in FVC, DLCO, and DLCO/alveolar volume was significantly higher than was that found in a group of COPD patients.\textsuperscript{[30]}

In another study, the rate of decline in lung volume was found to be considerably lower in patients with CPFE than in those with IPF.\textsuperscript{[31]}

Although DLCO values were lower in the patients with CPFE than in those with IPF, the annual rate of decline in DLCO was also significantly lower in the former. There were no differences between the two groups in terms of survival.\textsuperscript{[31]}

One possible explanation for normal or subnormal spirometry results despite severe impairment in DLCO is that hyperinflation and greater lung compliance as a result of loss of elasticity in the areas of emphysema can compensate for the losses in volume and lung compliance caused by fibrosis. Another plausible explanation is that fibrosis prevents the early small airway closure observed in patients with emphysema.

Although a single spirometry test can underestimate the severity of the disease, Schmidt et al. demonstrated that a progressive approach,
with a longitudinal decline in FEV₁, can accurately define disease progression and predict mortality in CPFE patients.\(^{12}\) In addition, the authors found a correlation between the extent of emphysema on HRCT scans and the decline in FEV₁.\(^{12}\)

### PAH in CPFE

The prevalence of PAH is exceedingly high in patients with CPFE, and PAH correlates with worse survival.\(^{3,33,34}\) The prevalence of PAH in CPFE patients varies from 47% to 90%, being considerably higher than that in patients with COPD or IPF alone.\(^{18}\) Indeed, the five-year survival rate in a study involving CPFE patients was 25% in those with PAH (as measured by transthoracic echocardiography), being 75% in those without PAH.\(^{28}\) In another study, the finding of severe PAH on echocardiography was associated with an increased risk of death.\(^{15}\)

Mejia et al. conducted a study in Mexico, in which PAH was assessed by transthoracic echocardiography in a cohort of patients with IPF (with and without emphysema). Not only was PAH more prevalent in the patients with CPFE, but it was also responsible for a worse...
Combined pulmonary fibrosis and emphysema: an increasingly recognized condition

CTD-associated CPFE; however, no randomized trials have been conducted. Lung transplantation is the only option that can improve survival.

The major causes of death in patients with CPFE are chronic respiratory failure, PAH, acute exacerbation, and lung cancer. Usui et al. found an 8.9% prevalence of CPFE in 1,143 consecutive patients with primary lung cancer in Japan. The authors showed that, in comparison with patients with fibrosis or emphysema alone, CPFE patients had a worse survival and an increased incidence of acute exacerbation after surgery.

Variations in DLCO, hypoxemia, digital clubbing, mean pulmonary artery pressure, and decline in FEV1 are considered better surrogates for disease progression and higher risk of mortality, allowing earlier evaluation for transplantation. Recently, Chiba et al. demonstrated that two biomarkers of fibrosis, namely KL-6 and surfactant protein D, are good indicators of the extent of fibrosis in patients with CPFE. High KL-6 and surfactant protein D levels were found to correlate negatively with all lung volumes and with DLCO. Kishaba et al. demonstrated that high levels of KL-6 are predictors of acute exacerbations in patients with CPFE.

The prognosis and overall mortality of CPFE patients in comparison with those of IPF and COPD patients is still a matter of debate. Different enrollment criteria, duration of follow-up, heterogeneity of patients (including type of emphysema), retrospective data analysis, and lead-time bias might explain the heterogeneity of results.

As is the case with IPF, there is currently no effective treatment for CPFE, with the exception of smoking cessation and lung transplantation (for patients with advanced disease). Bronchodilators, however, can be prescribed to patients with a positive response to bronchodilators in pulmonary function tests. Cottin et al. recommended the use of N-acetylcysteine (1.8 g/day) on the basis of the results of studies investigating IPF. Oral corticosteroids and immunosuppressants have been considered an option in the setting of treatment and prognosis.
(as determined by pulmonary function tests) and better survival in patients with CPFE. In addition, there were no differences in DLCO among those groups of patients.\textsuperscript{39,40}

Another hypothesis for centrilobular emphysema acting as a “protective factor” is based on the fact that centrilobular emphysema is essentially caused by tobacco exposure. Some in vitro studies have shown that the proinflammatory cytokines seen in cases of cigarette smoking and emphysema have antifibrotic properties; therefore, such patients might have smaller areas of fibrosis and a better prognosis.\textsuperscript{48} Paraseptal emphysema might represent another lung response to smoking, leading to severe pulmonary fibrosis, or simply reflect a greater extent of fibrosis in lower lung zones, exerting traction on lung tissue located in the apices. However, the fibrotic areas seen on chest X-rays do not precede the onset of emphysema, indicating that both processes probably occur simultaneously.

Corroborating this theory, Kurashima et al. found that a greater extent of emphysema on CT scans correlated with better pulmonary function parameters and a better prognosis in comparison with those in a group of patients with IPF.\textsuperscript{49} The authors did not classify emphysema into subtypes and suggested that emphysema is a protective factor in patients with CPFE.\textsuperscript{50} Similar findings were reported by Ando et al.\textsuperscript{51} in a study examining the relationship between pulmonary function and CT quantification of emphysema and fibrosis in CPFE, the authors having concluded that pulmonary fibrotic changes contribute more to the progression of CPFE than does emphysema.\textsuperscript{52}

The mortality rates for CPFE and IPF are similar.\textsuperscript{63,64} Recently, Ryerson et al. compared CPFE-IPF patients with non-CPFE IPF patients.\textsuperscript{45} Although the patients with CPFE had a more extensive smoking history, greater oxygen requirements, higher pulmonary artery pressure, less restrictive physiology, and lower diffusing capacity, there was no significant difference in mortality between the two groups.\textsuperscript{45}

Final considerations

Pulmonologists have been accustomed to recognizing fibrosis and emphysema as two well-defined diseases. However, a large body of evidence has shown that an overlap can exist, CPFE being therefore a new entity, with unique features. In view of the fact that most studies investigating CPFE have had a retrospective design, more studies are needed to address the role of emphysema and its subtypes, the progression of fibrosis/emphysema and its correlation with inflammation, treatment options (including the treatment of PAH), and prognosis in CPFE patients. A deeper understanding of the pathophysiology and progression of CPFE is urgently required in order to improve its management, given that there is currently no effective treatment for the disease.

References

1. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med. 1990;84(5):365-9. http://dx.doi.org/10.1016/S0954-6111(08)80070-4
2. Grubstein A, Bendayan D, Schactman I, Cohen M, Shitrit D, Kramer MR. Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respir Med. 2005;99(8):948-54. http://dx.doi.org/10.1016/j.rmed.2004.12.010
3. Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586-93. http://dx.doi.org/10.1183/09031936.05.00021005
4. Cottin V, Nunes H, Mouthon L, Gamondes D, Lazor R, Hachulla E, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum. 2011;63(1):295-304. http://dx.doi.org/10.1002/art.30077
5. Lubatti C, Zeni S, Ingegnoti F. Combined pulmonary fibrosis and emphysema syndrome in systemic sclerosis. Int J Rheum Dis. 2012;15(5):e122-3. http://dx.doi.org/10.1111/j.1756-185X.2012.01747.x
6. Cottin V, Freymond N, Cabane J, Cordier JF. Combined pulmonary fibrosis and emphysema syndrome in a patient age 28 years with severe systemic sclerosis. J Rheumatol. 2011;38(9):2082-3. http://dx.doi.org/10.3899/jrheum.101365
7. Cottin V, Cordier JF. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Curr Opin Pulm Med. 2012;18(5):418-27. http://dx.doi.org/10.1097/MCP.0b013e328356803b
8. Tsouvelakis A, Zacharis G, Oikonomou A, Koulelidis A, Steiropoulos P, Froudarakis M et al. Combined pulmonary fibrosis and emphysema associated with microscopic polyangiitis. Eur Respir J. 2012;40(2):505-7. http://dx.doi.org/10.1183/09031936.00216311
9. Tsouvelakis A, Zacharis G, Oikonomou A, Mikroulis D, Margaritopoulos G, Koutoupooulos A et al. Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema. BMC Pulm Med. 2013;13:31. http://dx.doi.org/10.1186/1471-2466-13-31
10. Kishaba T, Shimaoka Y, Fukuyama H, Yoshida K, Tanaka M, Yamashiro S, et al. A cohort study of mortality predictors.
Combined pulmonary fibrosis and emphysema: an increasingly recognized condition
37. Kwak N, Park CM, Lee J, Park YS, Lee SM, Yim JJ, et al. Lung cancer risk among patients with combined pulmonary fibrosis and emphysema. Respir Med. 2014;108(3):524-30. http://dx.doi.org/10.1016/j.rmed.2013.11.013

38. Chiba S, Ohta H, Abe K, Hisata S, Ohkouchi S, Hoshikawa Y, et al. The diagnostic value of the interstitial biomarkers KL-6 and SP-D for the degree of fibrosis in combined pulmonary fibrosis and emphysema. Pulm Med. 2012;2012:492960. http://dx.doi.org/10.1155/2012/492960

39. Todd NW, Jeudy J, Lavania S, Franks TJ, Galvin JR, Deepak J, et al. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Fibrogenesis Tissue Repair. 2011;4(1):6. http://dx.doi.org/10.1186/1755-1536-4-6

40. Todd NW, Atamas SP. Survival in pulmonary fibrosis combined with emphysema: likely defined by characteristics of specific patient subpopulations. Fibrogenesis Tissue Repair. 2011;4:17. http://dx.doi.org/10.1186/1755-1536-4-17

41. Kurashima K, Takayanagi N, Tsuchiya N, Kanauchi T, Ueda M, Hoshi T, et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respiriology. 2010;15(5):843-8. http://dx.doi.org/10.1111/j.1440-1843.2010.01778.x

42. Ando K, Sekiya M, Tobino K, Takahashi K. Relationship between quantitative CT metrics and pulmonary function in combined pulmonary fibrosis and emphysema. Lung. 2013;191(6):585-91. http://dx.doi.org/10.1007/s00408-013-9513-1

43. Jankowich MD, Polsky M, Klein M, Rounds S. Heterogeneity in combined pulmonary fibrosis and emphysema. Respiration. 2008;75(4):411-7. http://dx.doi.org/10.1159/000107048

44. Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung. 2010;188(5):365-73. http://dx.doi.org/10.1007/s00408-010-9251-6

45. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144(1):234-40. http://dx.doi.org/10.1378/chest.12-2403

About the authors

Olivia Meira Dias
Attending Physician. Department of Cardiorespiratory Diseases, Instituto do Coração – InCor, Heart Institute – University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.

Bruno Guedes Baldi
Attending Physician. Department of Cardiorespiratory Diseases, Instituto do Coração – InCor, Heart Institute – University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.

André Nathan Costa
Attending Physician. Department of Cardiorespiratory Diseases, Instituto do Coração – InCor, Heart Institute – University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.

Carlos Roberto Ribeiro Carvalho
Full Professor. Department of Cardiorespiratory Diseases, Instituto do Coração – InCor, Heart Institute – University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.